Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE) | MicrobiomeTrials← Back to trialsNCT04179032
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2019-11-28Est. Completion: 2023-01-16
Enrollment target: 25 participants Locations- GSK Investigational Site, Cincinnati, Ohio, United States
- GSK Investigational Site, Rosario, Argentina
- GSK Investigational Site, Berlin, Germany
- GSK Investigational Site, Saint Augustin, Germany
- GSK Investigational Site, Kagoshima, Japan
- GSK Investigational Site, Kanagawa, Japan
- GSK Investigational Site, San Luis Potosí City, Mexico
- GSK Investigational Site, Rotterdam, Netherlands
- GSK Investigational Site, Barcelona, Spain
- GSK Investigational Site, Madrid, Spain
- GSK Investigational Site, Valencia, Spain
Other microbiome trials you might be interested in
Rare DiseasesGeneralized Myasthenia Gravis (gMG)
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describ…
Kazan', RussiaEst. completion Dec 31, 2029
Systemic Lupus Erythematosus (SLE)
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic…
Phoenix, United StatesCompleted Mar 29, 2030
Phase 3
ENROLLING_BY_INVITATION
Lupus Erythematosus, Systemic
The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients w…
Aurora, United StatesCompleted Sep 2032